Meningococcal Vaccine Safety in Pregnancy
Meningococcal vaccines (both polysaccharide and conjugate formulations) are safe to administer during pregnancy and should be given when a pregnant woman is at high risk of meningococcal disease or during an outbreak. 1
Safety Profile
The evidence consistently demonstrates that meningococcal conjugate vaccines have not been associated with any safety concerns in pregnancy 1. Multiple studies support this conclusion:
A 2020 Kaiser Permanente study of 92 women who inadvertently received MenACWY-CRM during pregnancy (76% in first trimester) found adverse pregnancy outcomes comparable to U.S. background rates: spontaneous abortion (18.2%), preterm birth (14.5%), low birthweight (9.1%), and major congenital malformations (1.8%) 2
VAERS surveillance data (2005-2016) reviewing 13,075 reports after MenACWY-D found no evidence that reported deaths were related to vaccination. Among 103 pregnancy reports, 37% described no adverse events, with spontaneous abortion rates (16.5%) and one major congenital anomaly consistent with background rates 3, 4
A 2020 systematic review and meta-analysis concluded that meningococcal vaccines are probably safe during pregnancy, supported by RCTs comparing meningococcal vaccines to other vaccines 5
Additional Benefits
Beyond maternal safety, meningococcal vaccination during pregnancy provides measurable infant protection:
Vaccines are immunogenic and result in higher antibody concentrations in infants through transplacental transfer 1
A randomized controlled trial demonstrated that maternal immunization with polysaccharide meningococcal vaccine resulted in a 5.6-fold antibody rise in mothers, with infants maintaining significantly elevated IgG levels for 2-3 months and receiving protective IgA through breast milk for 6 months 6
Clinical Recommendations
Indications for vaccination during pregnancy:
- High-risk exposure (e.g., complement deficiencies, asplenia, complement inhibitor use)
- Outbreak situations
- Travel to endemic areas with significant exposure risk
Timing considerations: While the vaccine can be administered at any gestational age, many clinicians prefer second or third trimester administration to avoid theoretical first-trimester concerns, though no evidence supports harm during organogenesis 1
Important Caveats
The guideline notes there is no evidence about immunogenicity or effectiveness when meningococcal vaccines are specifically given during pregnancy for disease prevention 1. However, the established safety profile and demonstrated antibody transfer support use when indicated based on risk assessment rather than routine administration.
Both polysaccharide and conjugate vaccine platforms are considered safe for pregnancy use under appropriate circumstances 1.